{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-012086","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.322297+00:00","generated_at":"2026-06-25T17:32:47.820041+00:00","sec_items":["2.02","5.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Integrated BioPharma Q3 net income falls 36% to $0.8M; revenue $15.6M","bullets":["Q3 revenue $15.6M, down 8.4% YoY from $17.1M; operating income $1.0M vs $1.7M.","Net income $0.8M ($0.03 diluted EPS) vs $1.2M ($0.04) in prior-year quarter.","Nine-month revenue $43.0M, down 7.6%; net income $2.3M vs $3.5M.","Revenue decline attributed to normalization of customer safety stock from COVID-19 pandemic.","Two largest contract manufacturing customers still represent ~91% of total revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-012086","json":"https://secwatch.observer/filing/0001437749-22-012086.json","markdown":"https://secwatch.observer/filing/0001437749-22-012086.md","text":"https://secwatch.observer/filing/0001437749-22-012086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922012086/0001437749-22-012086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922012086/inbp20220511_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:32:47.820041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}